Results 91 to 100 of about 122,258 (265)

Intravenous Reelin rescues despair-like behavior, Reelin cells in the dentate sub-granular zone, and spleen atrophy in the cyclic corticosterone model of recurring depressive episodes

open access: yesFrontiers in Pharmacology
Novel antidepressants are predominantly evaluated preclinically in rodent models of chronic stress in which animals experience a single prolonged exposure to chronic stress prior to treatment. Rodent models of a single episode of chronic stress translate
B. S. Reive   +6 more
doaj   +1 more source

Different pH-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway.

open access: yesFrontiers in Pharmacology, 2015
The major drug binding site of sodium channels is inaccessible from the extracellular side, drug molecules can only access it either from the membrane phase, or from the intracellular aqueous phase.
Alexandra eLazar   +5 more
doaj   +1 more source

Characterization of Anticholinergic Medication Use and Its Associations With Everyday Memory Problems and Cognitive Decline in Autistic Adults With Higher Support Needs

open access: yesAutism Research, EarlyView.
ABSTRACT Among older adults in the general population, medications with anticholinergic (AC) effects are associated with declines in cognitive functioning and with dementia and Alzheimer's disease. Autistic people have high rates of co‐occurring medical conditions and polypharmacy across the lifespan; thus, they may be at particularly high risk of ...
Goldie A. McQuaid   +2 more
wiley   +1 more source

Effects of pharmacogenomics-guided treatment on medication adherence and the antidepressant switching rate in major depressive disorder

open access: yesFrontiers in Pharmacology
BackgroundIn the treatment of depression, medication plays a crucial role. However, insufficient patient adherence to medication often results in unsatisfactory treatment outcomes, increasing both the recurrence and rehospitalization rates of depression,
Chaoli Chen   +22 more
doaj   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou   +3 more
wiley   +1 more source

Characteristics and temporal trends of EU teratological safety signals and information dissemination to healthcare professionals in the Netherlands—A contribution of the ConcePTION project

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Although regulatory responses to safety signals have been studied, pregnancy‐specific data and their dissemination to medical professionals remain unclear. This study examined the characteristics and temporal trends of teratological safety signals prompting the European Medicines Agency to implement risk minimization measures.
Yrea R. J. van Rijt‐Weetink   +9 more
wiley   +1 more source

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller   +9 more
wiley   +1 more source

Sustained pharmacodynamic effects of S‐ketamine on cortical excitability and resting‐state brain activity: A randomized, placebo‐controlled trial

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to investigate a set of pharmacodynamic biomarkers reflecting acute, delayed and sustained central nervous system effects of S‐ketamine, used as a tool compound for rapid‐acting antidepressant activity, with the goal of informing biomarker strategies for delayed antidepressant effects.
Catherine M. K. E. de Cuba   +11 more
wiley   +1 more source

Secondary Trigeminal Neuralgia after a Brainstem Hemorrhagic Stroke with Adverse Reaction to Carbamazepine: A Case Report

open access: yesBali Journal of Anesthesiology
Secondary trigeminal neuralgia (TN) is a rare manifestation of neuropathic pain in post-stroke patients, which is characterized by paroxysmal unilateral pain in the trigeminal nerve distribution, especially in strokes that occur in the brainstem.
I Gusti Agung Ayu Andra Yusari   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy